Top Page
Vext Science
(OTC:VEXT)
Vext Science (VEXT) vs. iShares MSCI Canada ETF (EWC)
Vext Science Business Overview & Revenue Model
Vext Science Earnings Call Summary
Vext Science Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 36.00M | 34.81M | 35.41M | 37.24M | 25.19M |
| Gross Profit | 8.98M | 12.04M | 23.10M | 18.69M | 11.20M |
| EBITDA | -2.02M | 16.77M | 15.03M | 12.80M | 5.52M |
| Net Income | -22.44M | 4.40M | 10.92M | 4.99M | 2.13M |
Balance Sheet | |||||
| Total Assets | 136.97M | 149.56M | 120.52M | 83.70M | 55.45M |
| Cash, Cash Equivalents and Short-Term Investments | 4.62M | 8.72M | 5.93M | 6.47M | 1.75M |
| Total Debt | 39.52M | 38.60M | 38.15M | 14.10M | 11.49M |
| Total Liabilities | 61.23M | 54.58M | 48.60M | 24.31M | 19.14M |
| Stockholders Equity | 75.74M | 94.98M | 71.92M | 59.39M | 36.31M |
Cash Flow | |||||
| Free Cash Flow | 1.82M | 1.69M | -2.94M | -7.10M | -964.90K |
| Operating Cash Flow | 3.29M | 4.42M | 5.92M | 11.68M | 3.10M |
| Investing Cash Flow | -5.44M | -4.82M | -30.31M | -27.10M | -12.90M |
| Financing Cash Flow | -1.95M | 3.19M | 23.86M | 20.14M | 4.26M |
Vext Science Technical Analysis
Vext Science Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | C$43.33M | ― | -24.12% | ― | 18.82% | -9328.57% | |
46 Neutral | C$194.28M | -4.22 | -8.60% | 2.64% | 13.54% | -1.44% | |
| $21.40M | ― | -16.22% | ― | ― | ― | ||
| $29.73M | 3.27 | 20.78% | ― | ― | ― | ||
| $19.10M | ― | -12.58% | ― | ― | ― | ||
| $22.20M | ― | -2.68% | ― | ― | ― | ||
44 Neutral | C$32.88M | ― | -31.24% | ― | 44.21% | 21.93% |
Vext Science Corporate Events
Vext Science, Inc. has secured a provisional license for its sixth cannabis dispensary in Fairfield, Ohio, with operations expected to commence in the fourth quarter of 2025, subject to regulatory approvals. This strategic expansion highlights Vext’s disciplined approach to growth, leveraging high-traffic locations and limited competition to drive cash flow and shareholder value. The new Fairfield location, adjacent to Jungle Jim’s International Market, is expected to enhance visibility and consumer traffic, further solidifying Vext’s market position in Ohio as it approaches the state’s dispensary license cap of eight.
The most recent analyst rating on (TSE:VEXT) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.
Vext Science, Inc. has opened its fifth cannabis dispensary in Portsmouth, Ohio, enhancing its retail footprint in the state. The new location, which includes a drive-thru, is part of Vext’s strategy to scale its operations and increase market presence in Ohio, a key growth area for the company. The Portsmouth dispensary is expected to be fully consolidated by late 2025, subject to regulatory approval. Vext’s vertically integrated model in Ohio positions it to drive margin expansion and free cash flow, supporting its long-term growth and shareholder value.
The most recent analyst rating on (TSE:VEXT) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.
Vext Science, Inc. has announced a change of auditor from Reliant CPA to MNP LLP, effective June 4, 2025. The change was initiated by the former auditor due to the company’s growth exceeding its audit practice’s scope. The new auditor, MNP LLP, is expected to better meet Vext’s financial reporting needs due to its greater public company experience. The transition is not associated with any reservations or reportable events, and has been approved by the board.
The most recent analyst rating on (TSE:VEXT) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.
Vext Science reported a record Q1 performance with $11.6 million in revenue, a 38% increase from Q1 2024, driven by growth in Ohio. The company’s operating cash flow reached $3.1 million, matching its entire 2024 cash generation, highlighting the success of its retail strategy. Vext doubled its Ohio retail footprint by acquiring two dispensaries, enhancing its market presence. The company is focused on expanding in Ohio, reducing debt, and delivering sustainable returns for shareholders.
The most recent analyst rating on (TSE:VEXT) stock is a Buy with a C$0.60 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.
Vext Science, Inc. announced it will release its Q1 2025 financial results on May 21, 2025, before the market opens. The company will also host a conference call and webcast to discuss these results, reflecting its continued focus on growth and stakeholder engagement in its core markets of Arizona and Ohio.
The most recent analyst rating on (TSE:VEXT) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.
Vext Science, Inc. has announced the sale of its medical cannabis processing license in Kentucky for $880,000, as part of a strategic move to concentrate on its core markets in Arizona and Ohio. The transaction is expected to bolster Vext’s balance sheet, aiding in the expansion of its retail operations in Ohio and supporting general corporate purposes. This decision reflects Vext’s disciplined capital allocation strategy and commitment to maximizing returns in its primary operational areas.